Significance of cardiac and iron profile alteration in diabetic patients

This study was conducted on 120 subjects. Subjects were divided into two main groups (80 diabetic patients and 40 healthy controls); diabetic subjects were subdivided into two subgroups (G-IIa and G-IIb) according to fasting blood glucose and glycosylated hemoglobin (HbA1c). Serum iron profile (iron, total iron binding capacity, and percentage transferrin saturation) is calculated as the index of iron. Lactate dehydrogenase (LDH), total creatine kinase (CK), and creatine kinase-MB (CK-MB) activities are measured as an index of cardiac functions. Also, fasting blood glucose and HbA1c were assayed. Diabetic patients were characterized by a significant elevation in the fasting blood glucose, HbA1c, cardiac enzyme activities, iron level, and percentage transferrin saturation as compared to normal healthy control, while diabetic patients showed a significant decrease in the total iron binding capacity as compared to normal healthy subjects. Our current study suggests that iron is one of the causative factors for diabetes and diabetic complications.
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

Publication date: Available online 14 November 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Mariceli Comellas, Yamile Marrero, Florence George, Lisa MatthewsAbstractAimTo assess the age and its association with glycemic control (GC) among adults with type 2-diabetes in the United States.Materials and MaterialsData were collected from the National Nutrition Examination Survey (NHANES) 2013 -2014 (n=697), cross-sectional national survey adults with Type2 diabetes. Characteristics included retinopathy diagnosis, blood pressure, albumin-creatinine ratio, hemoglobin A1c (HbA1c), BMI, ch...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
ConclusionSerum CysC is shown to be a superior biomarker in the early diagnosis of DN. However, further studies are still needed to verify our claims.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
ConclusionCo-administration of Rg3-KRG+AG is an effective add-on for improving BP along with attaining favorable cardiometabolic outcomes in individuals with type 2 diabetes. Ginseng derivatives may offer clinical utility when included in the polypharmacy and lifestyle treatment of diabetes.Graphical abstract
Source: Journal of Ginseng Research - Category: Complementary Medicine Source Type: research
The objective of this study was 1) to assess the relationship between diagnosed DLP and cardiovascular disease in COPD patients and compare it with other known cardiovascular risk factors and 2) to determine the relationship between the different cardiovascular comorbidities and the severity groups according to the GOLD 2017 classification.MethodsA cross-sectional, observational study was performed in 454 outpatients with COPD during their follow up. We calculated the prevalence of each of the cardiovascular comorbidities and the probability of each of the cardiovascular risk factors to occur jointly with a vascular diseas...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Finding the'missing'people walking around with undiagnosed type 2 diabetes, estimated at around 1 in 70 of the population, will require screening, but the question is how, say experts.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
TYPE 1 and type 2 diabetes are two well established conditions that affect a person ’s blood sugar control. But another type of diabetes, type 1.5 diabetes, is beginning to gain traction - what is it, and are you at risk?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
The findings of recent clinical trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors produce effects beyond glucose lowering and have demonstrated beneficial cardiovascular effects that have been observed across a broad range of patients with type 2 diabetes mellitus. In particular, the cardiovascular benefit results largely from substantial and early effects of SGLT2 inhibition on cardiovascular death and hospitalization for heart failure. Recent cardiovascular outcomes trials (CVOTs) have also shown that relative risk reductions in cardiovascular outcomes were observed with SGLT2 inhibition both in p...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Sodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease progresses and are the first agents to do so since the advent of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Salutary effects on the kidney were first demonstrated in cardiovascular outcomes trials and have now emerged from trials enriched in subjects with type 2 diabetes mellitus and chronic kidney disease.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Heart failure is a common complication among patients with type 2 diabetes mellitus and is associated with significantly increased risks of subsequent morbidity and mortality. Until recently, therapies and strategies were lacking to attenuate this excess risk of heart failure in this population. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a unique class of glucose-lowering therapies that have multisystem health benefits. Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atheroscleroti...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Type 2 diabetes mellitus has long been recognized as a major risk factor for adverse atherosclerotic cardiovascular disease events; however, recent data indicate that heart failure is now emerging as the most common and morbid cardiovascular complication of type 2 diabetes mellitus. When heart failure develops in patients with type 2 diabetes, prognosis is ominous, highlighting the need for glucose-lowering therapies that can prevent heart failure, improve outcomes, or both. Prior to 2008, there was a paucity of randomized controlled trials evaluating long-term cardiovascular outcomes with glucose-lowering therapies.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Pathology | Study